Ivan Kairatov is a Biopharma expert, with profound knowledge in technology and innovation in the medical industry, and extensive experience in research and development. Today, we'll delve into a study from the University of Colorado Anschutz Medical Campus, discussing its significance for
Mirum Pharmaceuticals recently made headlines as they secured FDA approval for Ctexli, also known as chenodiol, as the first treatment for cerebrotendinous xanthomatosis (CTX). CTX, a rare genetic lipid storage disease, affects an estimated 3 to 5 individuals per 100,000. This approval came after a
Nanomedicine has made remarkable strides since the 1950s, revolutionizing the way drugs are delivered within the body. A recent breakthrough by scientists at ETH Zürich leverages sound waves to control microscopic flower-like zinc oxide particles for targeted drug delivery, marking a significant
Appendiceal cancer, a rare malignancy, presents significant challenges due to the lack of standardized screening guidelines, identifiable risk factors, and a common tumor classification system. These hurdles often result in delayed diagnoses and poor prognoses for patients. The estimated annual
In a significant effort to find alternative treatments for head and neck cancer patients who cannot use cisplatin due to its harmful side effects, researchers conducted a new clinical trial that unfortunately provided discouraging results. Cisplatin is a widely used chemotherapy drug known for its
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Can you tell us a little about your professional background and your role as a biopharma expert? Certainly. I have spent the last couple of decades working at
